Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia - Preliminary report

Medical Science Monitor

Volumn 7, Issue 1, 2001, Pages 125-129

  Łuczyński, Włodzimierz ^a   Muszyńska Rosłan, Katarzyna ^a   Krawczuk Rybak, Maryna ^a   Kuźmicz, Marta ^a   Iwaszkiewicz Pawłowska, Anna ^a   Kaliszewski, Jacek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acute myeloblastic leukaemia; Children; Fludarabine; IDA FLAG

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ADOLESCENT; ANEMIA; ARTICLE; BONE MARROW APLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LEUKOPENIA; MYELOID LEUKEMIA; RECURRENT CANCER; THROMBOCYTOPENIA;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOPENIA; RECURRENCE; THROMBOCYTOPENIA; TIME FACTORS; VIDARABINE;

EID: 0035143716     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. IDA-FLAG, an effective remission-induction therapy for poor prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a phase II trial
2. Wyniki leczenia dzieci z ostrq bialaczkq mieloblastycznq. Analiza pierwszych 3 miesiȩcy terapii
3. Conduct of phase I trials in children with cancer
4. New agents for treatment of children with acute myelogenous leukemia
5. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading bolusus followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias
6. IDA-FLAG - An effective therapy regimen in treatment of recurrent AML in children and adolescents. Initial results of a pilot study
7. Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: Successful engraftment with minimal toxicity
8. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
9. Central nervous system toxicity of fludarabine phosphate
10. FLAG for refractory and high-risk relapsed acute leukemia in children
11. A phase I/II study of Idarubicin (Ida) with continuous infusion Fludarabine (F-ara-A) and Cytarabine (ara-C) for refractory or reccurent pediatric Acute Myeloid Leukemia (AML)
12. FLAG for refractory and high-risk relapsed acute leukemia in children
13. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: A report from the Children's Cancer Group
14. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukemia patients